ClinicalTrials.gg

Program

mirdametinib

Also written as “Mirdametinib”, “PD-0325901” and “Mirdametinib (MEK Inhibitor)”.

Its studies are mostly in Neurofibroma, Plexiform · Melanoma · Carcinoma, Non-Small-Cell Lung, led by 3 companies.

Furthest: phase 2, since Apr 12, 20199 company-led studies, 4 open or runningNext primary completion: Nov 17, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germany64 open or runningphase 2since Apr 12, 2019Apr 12, 2019Nov 17, 2026phase 1 · NCT07840612
Pfizer20 open or runningphase 2since Sep 2, 2005Sep 2, 2005none ahead
BeOne Medicines10 open or runningphase 1since Apr 3, 2019Apr 3, 2019none ahead

Also a collaborator on its studies: springworks-therapeutics-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 2, 2005First studies: 2 phase 2 studiesNew to PfizerPfizer · NCT00147550, NCT00174369
  2. Apr 3, 2019BeOne Medicines's first study: phase 1 study in Solid Tumor, AdultNew to BeOne MedicinesBeOne Medicines · NCT03905148 · 91 enrolled · United States, Australia
  3. Apr 12, 2019Merck KGaA, Darmstadt, Germany's first study: phase 2 study in Neurofibroma, PlexiformNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT03962543 · 114 enrolled · United States
  4. Sep 22, 2022Phase 2 study in Advanced Solid TumorMerck KGaA, Darmstadt, Germany · NCT05580770 · 23 enrolled · United States, Australia
  5. May 5, 2025Phase 1 study in HealthyMerck KGaA, Darmstadt, Germany · NCT06997276 · 32 planned · United States
  6. Dec 1, 2025Phase 1 study in HealthyMerck KGaA, Darmstadt, Germany · NCT07279233 · 36 enrolled · United States
  7. Sep 18, 20262 phase 1 studiesMerck KGaA, Darmstadt, Germany · NCT07840612, NCT07850635

Ahead

  1. Nov 17, 2026Primary completion: phase 1 study in HealthyMerck KGaA, Darmstadt, Germany · NCT07840612
  2. Nov 27, 2026Primary completion: phase 1 study in HealthyMerck KGaA, Darmstadt, Germany · NCT06997276
  3. Oct 21, 2032Primary completion: phase 1 study in Neurofibromatosis Type 1-Associated Plexiform NeurofibromasMerck KGaA, Darmstadt, Germany · NCT07850635

TargetBeta

“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
cobimetinibruleHoffmann-La Rochephase 338
pimasertibruleMerck KGaA, Darmstadt, Germanyphase 213
polfurmetinibPfizerphase 13

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07850635Neurofibromatosis Type 1-Associated Plexiform Neurofibromas · Germany1Not yet recruitingMerck KGaA, Darmstadt, GermanyOct 21, 20326
NCT07840612Healthy · Germany1RecruitingMerck KGaA, Darmstadt, GermanyNov 17, 202617
NCT07279233Healthy · United States1CompletedMerck KGaA, Darmstadt, GermanyFeb 27, 202636
NCT06997276Healthy · United States1RecruitingMerck KGaA, Darmstadt, GermanyNov 27, 202632
NCT05580770Advanced Solid Tumor · United States, Australia2TerminatedMerck KGaA, Darmstadt, GermanyJan 15, 202523
NCT03962543Neurofibroma, Plexiform · United States2Active, not recruitingMerck KGaA, Darmstadt, GermanySep 20, 2023114
NCT03905148Solid Tumor, Adult · United States, Australia1CompletedBeOne MedicinesOct 9, 202491
NCT00174369Carcinoma, Non-Small-Cell Lung · United States2TerminatedPfizerJun 200734
NCT00147550Melanoma · United States2TerminatedPfizerMay 200779

How it is read

Names in the registry

  • “Mirdametinib”, 2 entries
  • “PD-0325901”, 2 entries
  • “Mirdametinib (MEK Inhibitor)”, 1 entry
  • “Mirdametinib (PD-0325901) oral capsule or dispersible tablet”, 1 entry
  • “Mirdametinib 2mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.